Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07548476 · ClinicalTrials.gov registry record · NA

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

A NA study, sponsored by Dana-Farber Cancer Institute.

Not yet
Registry status
NA
Development phase
50
Enrollment target

NCT07548476 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07548476, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.

NOT YET RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro). The names of the two study groups in this research study are: * Acupuncture + Virtual Exercise (AVE) * Virtual Exercise Only (VE)

Interventions

  • BEHAVIORAL Exercise
  • PROCEDURE Acupuncture

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-10-02
Est. Completion 2027-03-02
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT07548476

The ClinicalTrials.gov registry entry for NCT07548476 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Exercise is the first listed.

NCT07548476 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07548476 about?

NCT07548476 is a clinical study titled "Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy". The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizuma...

What is the current status of trial NCT07548476?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-10-02. Estimated completion is 2027-03-02.

What interventions are being tested in trial NCT07548476?

The interventions under investigation include: Exercise (BEHAVIORAL), Acupuncture (PROCEDURE).

Who is sponsoring clinical trial NCT07548476?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.